186 related articles for article (PubMed ID: 28978016)
1. Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients.
Armas-López L; Piña-Sánchez P; Arrieta O; de Alba EG; Ortiz-Quintero B; Santillán-Doherty P; Christiani DC; Zúñiga J; Ávila-Moreno F
Oncotarget; 2017 Sep; 8(40):67056-67081. PubMed ID: 28978016
[TBL] [Abstract][Full Text] [Related]
2. Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer.
Peralta-Arrieta I; Trejo-Villegas OA; Armas-López L; Ceja-Rangel HA; Ordóñez-Luna MDC; Pineda-Villegas P; González-López MA; Ortiz-Quintero B; Mendoza-Milla C; Zatarain-Barrón ZL; Arrieta O; Zúñiga J; Ávila-Moreno F
Eur J Cancer; 2022 Jan; 160():189-205. PubMed ID: 34844838
[TBL] [Abstract][Full Text] [Related]
3. LncRNA SOX2-OT regulates AKT/ERK and SOX2/GLI-1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases.
Herrera-Solorio AM; Peralta-Arrieta I; Armas López L; Hernández-Cigala N; Mendoza Milla C; Ortiz Quintero B; Catalán Cárdenas R; Pineda Villegas P; Rodríguez Villanueva E; Trejo Iriarte CG; Zúñiga J; Arrieta O; Ávila-Moreno F
Mol Oncol; 2021 Apr; 15(4):1110-1129. PubMed ID: 33433063
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of MEOX2 and TWIST1 is associated with H3K27me3 levels and determines lung cancer chemoresistance and prognosis.
Ávila-Moreno F; Armas-López L; Álvarez-Moran AM; López-Bujanda Z; Ortiz-Quintero B; Hidalgo-Miranda A; Urrea-Ramírez F; Rivera-Rosales RM; Vázquez-Manríquez E; Peña-Mirabal E; Morales-Gómez J; Vázquez-Minero JC; Téllez-Becerra JL; Ramírez-Mendoza R; Ávalos-Bracho A; de Alba EG; Vázquez-Santillán K; Maldonado-Lagunas V; Santillán-Doherty P; Piña-Sánchez P; Zúñiga-Ramos J
PLoS One; 2014; 9(12):e114104. PubMed ID: 25460568
[TBL] [Abstract][Full Text] [Related]
5. Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
Bora-Singhal N; Perumal D; Nguyen J; Chellappan S
Neoplasia; 2015 Jul; 17(7):538-51. PubMed ID: 26297432
[TBL] [Abstract][Full Text] [Related]
6. GLI1 activation is a key mechanism of erlotinib resistance in human non-small cell lung cancer.
Dong Z; Wang Y; Ding V; Yan X; Lv Y; Zhong M; Zhu F; Zhao P; He C; Ding F; Shi H
Oncol Lett; 2020 Oct; 20(4):76. PubMed ID: 32863909
[TBL] [Abstract][Full Text] [Related]
7. High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.
Takam Kamga P; Swalduz A; Costantini A; Julié C; Emile JF; Pérol M; Avrillon V; Ortiz-Cuaran S; de Saintigny P; Leprieur EG
Front Oncol; 2021; 11():747692. PubMed ID: 34970481
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of MEOX2 in gliomas.
Tachon G; Masliantsev K; Rivet P; Petropoulos C; Godet J; Milin S; Wager M; Guichet PO; Karayan-Tapon L
Mod Pathol; 2019 Jun; 32(6):774-786. PubMed ID: 30659268
[TBL] [Abstract][Full Text] [Related]
9. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
10. MEOX2 homeobox gene promotes growth of malignant gliomas.
Schönrock A; Heinzelmann E; Steffl B; Demirdizen E; Narayanan A; Krunic D; Bähr M; Park JW; Schmidt C; Özduman K; Pamir MN; Wick W; Bestvater F; Weichenhan D; Plass C; Taranda J; Mall M; Turcan Ş
Neuro Oncol; 2022 Nov; 24(11):1911-1924. PubMed ID: 35468210
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines.
Mizuarai S; Kawagishi A; Kotani H
Mol Cancer; 2009 Jul; 8():44. PubMed ID: 19575820
[TBL] [Abstract][Full Text] [Related]
12. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Yu HA; Goto Y; Hayashi H; Felip E; Chih-Hsin Yang J; Reck M; Yoh K; Lee SH; Paz-Ares L; Besse B; Bironzo P; Kim DW; Johnson ML; Wu YL; John T; Kao S; Kozuki T; Massarelli E; Patel J; Smit E; Reckamp KL; Dong Q; Shrestha P; Fan PD; Patel P; Sporchia A; Sternberg DW; Sellami D; Jänne PA
J Clin Oncol; 2023 Dec; 41(35):5363-5375. PubMed ID: 37689979
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the
Vad-Nielsen J; Staunstrup NH; Kjeldsen ML; Dybdal N; Flandin G; De Stradis C; Daugaard TF; Vilsbøll-Larsen T; Maansson CT; Doktor TK; Sorensen BS; Nielsen AL
Transl Lung Cancer Res; 2023 Jan; 12(1):42-65. PubMed ID: 36762066
[TBL] [Abstract][Full Text] [Related]
14. MEOX2-mediated regulation of Cathepsin S promotes cell proliferation and motility in glioma.
Wang J; Chen Y; Wang Q; Xu H; Wu C; Jiang Q; Wu G; Zhou H; Xiao Z; Chen Y; Zhang T; Lan Q
Cell Death Dis; 2022 Apr; 13(4):360. PubMed ID: 35436995
[TBL] [Abstract][Full Text] [Related]
15. A Crucial Angiogenesis-Associated Gene MEOX2 Could Be a Promising Biomarker Candidate for Breast Cancer.
Wang H; Tang Y; Yang X; Wang W; Han P; Zhao J; He S; Liu P
Front Oncol; 2022; 12():759300. PubMed ID: 35615155
[TBL] [Abstract][Full Text] [Related]
16. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.
Chang IS; Jiang SS; Yang JC; Su WC; Chien LH; Hsiao CF; Lee JH; Chen CY; Chen CH; Chang GC; Wang Z; Lo FY; Chen KY; Wang WC; Chen YM; Huang MS; Tsai YH; Su YC; Hsieh WS; Shih WC; Shieh SH; Yang TY; Lan Q; Rothman N; Chen CJ; Chanock SJ; Yang PC; Hsiung CA
Am J Respir Crit Care Med; 2017 Mar; 195(5):663-673. PubMed ID: 27669169
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Mesenchyme Homeobox 2 (MEOX2) transcription factor binding to RING finger protein 10.
Lin J; Friesen MT; Bocangel P; Cheung D; Rawszer K; Wigle JT
Mol Cell Biochem; 2005 Jul; 275(1-2):75-84. PubMed ID: 16335786
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
[TBL] [Abstract][Full Text] [Related]
20. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
